$13.39 -0.99 (%) Nektar Therapeutics - NASDAQ

Jun. 27, 2016 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Weekly CEO Sells Highlight: Monolithic Power Systems, Five Prime Therapeutics, Nektar Therapeutics

    GuruFocus | Feb. 15, 2016 | 12:58PM EST
  2. Weekly CEO Sales Highlight: Monolithic Power Systems, Five Prime Therapeutics, Nektar Therapeutics

    GuruFocus | Feb. 14, 2016 | 14:30PM EST
  3. Benzinga's Top Initiations

    Benzinga | Jan. 28, 2016 | 09:53AM EST
  4. Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine

    Benzinga | Dec. 8, 2015 | 09:00AM EST
  5. Baxalta Announces U.S. Availability of ADYNOVATE, New Treatment for Adult Patients With Hemophilia A With a Simple, Twice-Weekly Dosing Schedule

    Benzinga | Nov. 30, 2015 | 06:45AM EST
  6. Endologix, Express, Rockwell Automation Lead After-Hours Movers To Close Holiday Week

    Benzinga | Nov. 27, 2015 | 15:19PM EST
  7. Baxalta Announces FDA Approval of ADYNOVATE Treatment for Hemophilia A

    Benzinga | Nov. 14, 2015 | 08:08AM EST
  8. Nektar Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies

    Benzinga | Oct. 7, 2015 | 08:45AM EST
  9. Nektar Announces Receipt of $40 Million Milestone Payment Resulting from First Commercial Sale of MOVENTIG® (naloxegol) Tablets in Major European Market

    Benzinga | Sep. 1, 2015 | 08:31AM EST
  10. Baxalta's BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A

    Benzinga | Jul. 16, 2015 | 08:33AM EST
  11. Mid-Morning Market Update: Markets Open Lower; Lennar Beats Q2 Estimates

    Benzinga | Jun. 24, 2015 | 10:20AM EST
  12. 5 Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years

    Benzinga | Feb. 20, 2015 | 09:36AM EST
  13. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2

    Benzinga | Jan. 12, 2015 | 11:03AM EST
  14. What Investors Are Expecting Ahead Of Multiple Nektar Therapeutics Catalysts

    Benzinga | Jan. 9, 2015 | 12:53PM EST
  15. 5 Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years

    Benzinga | Jan. 9, 2015 | 09:19AM EST
  16. Nektar Offers Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of NKTR-102

    Benzinga | Dec. 11, 2014 | 18:03PM EST
  17. Nektar Presents Positive Preclinical Data On Oral, Peripherally-Acting Kappa Agonist Molecules At 2014 American Academy Of Pain Management Meeting

    Benzinga | Sep. 19, 2014 | 09:01AM EST
  18. Progenics, Nektar Still Halted; FDA Advisory Committee Expected To Conclude Thursday

    Benzinga | Jun. 12, 2014 | 09:41AM EST
  19. Top Healthcare Movers For June 9, 2014

    Benzinga | Jun. 9, 2014 | 14:27PM EST
  20. Small Pharmaceuticals Rallying Following FDA Report

    Benzinga | Jun. 9, 2014 | 12:49PM EST
  21. Nektar Therapeutics Prices 8.5M Share Offering at $12.75/Share

    Benzinga | Jan. 22, 2014 | 22:50PM EST
  22. Nektar Therapeutics Announces Public Offering of 8.5M Shares of Common Stock

    Benzinga | Jan. 21, 2014 | 16:14PM EST
  23. Nektar Presents Positive Data from Phase 1 Study of Etirinotecan Pegol in Combination with 5-Flourouracil/Leucovorin at 2014 Gastrointestinal Cancers Symposium

    Benzinga | Jan. 18, 2014 | 12:34PM EST
  24. Etirinotecan Pegol Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer

    Benzinga | Jan. 14, 2014 | 08:18AM EST
  25. UPDATE: Piper Jaffray Initiates Coverage on Nektar Therapeutics on Expected Attractive Returns

    Benzinga | Nov. 27, 2013 | 10:53AM EST
  26. Nektar, Astra Zeneca Announce NDA for Naloxegol Accepted by FDA

    Benzinga | Nov. 19, 2013 | 07:07AM EST
  27. Market Wrap For November 8: Markets Erase Thursday's Losses; Dow Companies Dominate Headlines

    Benzinga | Nov. 8, 2013 | 16:57PM EST
  28. Nektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day

    Benzinga | Oct. 8, 2013 | 11:15AM EST
  29. Nektar Reports AstraZeneca Receives EMA Acceptance of Marketing Authorization Application for Naloxegol

    Benzinga | Sep. 30, 2013 | 05:41AM EST
  30. Market Wrap For Friday, September 27: Dow Ends The Week Negative For First Time In Month

    Benzinga | Sep. 27, 2013 | 16:29PM EST
  31. Mid-Afternoon Market Update: Cerner Rallies Major Contract While United Airlines Plummets

    Benzinga | Sep. 27, 2013 | 15:51PM EST
  32. Mid-Day Market Update: Finish Line Gains On Upbeat Results; JC Penney Shares Fall

    Benzinga | Sep. 27, 2013 | 12:44PM EST
  33. William Blair Reiterates Outperform Nektar Therapeutics Following NKTR-181 Phase 2 Trial Miss

    Benzinga | Sep. 27, 2013 | 11:14AM EST
  34. UPDATE: Brean Capital Lowers PT on Nektar Therapeutics Following NKTR-181 Phase 2 Trial Miss

    Benzinga | Sep. 27, 2013 | 11:14AM EST
  35. Mid-Morning Market Update: Markets Open Lower; BlackBerry Reports Q2 Loss

    Benzinga | Sep. 27, 2013 | 10:48AM EST
  36. Benzinga's Top Pre-Market Losers

    Benzinga | Sep. 27, 2013 | 08:12AM EST
  37. Nektar Says Results from Phase 2 Trial of NKTR-181 Missed Primary Efficacy Endpoint

    Benzinga | Sep. 26, 2013 | 16:11PM EST
  38. Market Wrap For Monday, August 12: Stocks Close Mixed To Start Week

    Benzinga | Aug. 12, 2013 | 16:42PM EST
  39. Mid-Afternoon Market Update: Silver Continues Strong Rally as Sarepta Remains Down

    Benzinga | Aug. 12, 2013 | 15:33PM EST
  40. Mid-Day Market Update: Markets Slump; Facebook Remains Up on Massive Volume

    Benzinga | Nov. 14, 2012 | 07:14AM EST
  41. UPDATE: Bank of America Lowers Nektar Therapeutics PO, Maintains Underperform

    Benzinga | Nov. 13, 2012 | 02:52AM EST
  42. Nektar Therapeutics Plunges on FDA Worries, Downgrade

    Benzinga | Nov. 12, 2012 | 08:42AM EST
  43. A Peek Into The Market Before The Trading Starts

    Benzinga | Nov. 12, 2012 | 00:17AM EST
  44. AstraZeneca Announces Positive Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation

    Benzinga | Nov. 11, 2012 | 23:39PM EST
  45. Stocks Hitting 52-Week Highs

    Benzinga | Sep. 27, 2012 | 04:08AM EST
  46. Nektar Therapeutics Says Got Positive Data from Phase 1a Study of NKTR-192

    Benzinga | Sep. 18, 2012 | 03:26AM EST
  47. Nektar Therapeutics Reports Operating Results (10-Q)

    GuruFocus | Aug. 9, 2012 | 13:33PM EST
  48. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181

    Benzinga | Jul. 24, 2012 | 02:01AM EST
  49. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181

    Benzinga | Jun. 7, 2012 | 02:05AM EST
  50. Top 4 Small-Cap Stocks In The Biotechnology Industry With The Highest Cash

    Benzinga | Jun. 3, 2012 | 21:39PM EST
Trading Center